Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853, Debt stock code: 40168)

(1) RESUMPTION GUIDANCE; AND (2) CONTINUED SUSPENSION OF TRADING

This announcement is made by MicroPort Scientific Corporation (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09(2) and 37.47B(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the announcement of the Company dated 31 August 2026 in relation to, among other things, the delay in publication of its interim results for the six months ended 30 June 2026 and the suspension of trading in the shares of the Company (the "**Shares**") (stock code: 853) and the debt securities of the Company (debt stock code: 40168) on the Stock Exchange.

RESUMPTION GUIDANCE

On 17 November 2026, the Company received a letter from the Stock Exchange setting out the following guidance for the resumption of trading in the Shares (the "**Resumption Guidance**"):

(a) conduct an appropriate independent forensic investigation into the lease agreements with Shanghai BlueOrange Capital Corp., as landlord, for an industrial facility in Shanghai, the numerous transactions between Real & Realistic Foundation Limited and the Group or the family of Dr. Zhaohua Chang ("**Dr. Chang**") over a prolonged period, and any other transactions or arrangements giving rise to similar concerns (the "**Independent Forensic Investigation**"), assess the impact on the Company's business operations and financial position, announce the findings and take appropriate remedial actions;

(b) demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations (in particular, Dr. Chang), which may pose a risk to investors and damage market confidence;

(c) engage an independent internal control consultant to conduct an independent internal control review (the "**Independent Internal Control Review**") and demonstrate that: (i) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and (ii) the internal controls of the Company are adequate and effective to serve their purposes and enable the Company to comply with the Listing Rules and other legal and regulatory requirements, including but not limited to, financial reporting, disclosure and compliance relating to notifiable and connected transactions, and disclosure of inside information;

(d) publish all outstanding financial results required under the Listing Rules and address any audit modifications;

(e) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules; and

(f) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position.

The Company must meet all Resumption Guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange's satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. Whilst the Company may seek the Stock Exchange's guidance on its resumption plan, its resumption plan is not subject to the prior approval from the Stock Exchange before implementation. The Stock Exchange further stated that it may modify or supplement the Resumption Guidance if the Company's situation changes.

Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period will expire on **29 February 2028**. If the Company fails to remedy the issues causing its trading suspension, fulfil the Resumption Guidance, fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in the Shares by **29 February 2028**, the Listing Division will recommend that the Listing Committee proceed with the cancellation of the Company's listing. Under Rules 6.01 and 6.10 of the Listing Rules, the Stock Exchange also has the right to impose a shorter specific remedial period or to cancel the listing of the Company immediately, where appropriate.

The Resumption Guidance further stated that the Company must comply with its continuing obligations under the Listing Rules and all applicable laws and regulations in Hong Kong and its place of incorporation at all times, keep the duration of the trading suspension to the shortest possible period, announce inside information required to be disclosed under Part XIVA of the Securities and Futures Ordinance, and announce quarterly updates on its developments under Rule 13.24A of the Listing Rules, including its business operations, its resumption plan (with a timeframe for each stage of work), the progress of implementing the resumption plan and details of any material change to the resumption plan. The Company must announce its first quarterly update on or before 30 November 2026 and every three months thereafter until the resumption of trading or the cancellation of its listing (whichever is earlier).

Actions taken and to be taken by the Group

Since the suspension of the trading in the Shares, the Company has been proactively taking various measures with a view to resuming the trading of the Shares as soon as practicable.

As set out in the announcement of the Company dated 23 October 2026, the Company has adopted measures to enhance its corporate governance, and has strengthened its management structure, whereby the Company has implemented a CEO-led management structure under which Mr. Jonathan W. Chen, the chief executive officer and executive director of the Company will be accountable to, and report directly to, the board of directors of the Company (the "**Board**") and will assume overall responsibility for the day-to-day management and operations of the Company.

The Company will promptly take all necessary steps to fulfil the Resumption Guidance, remedy the issues causing its trading suspension and comply with the Listing Rules to the Stock Exchange's satisfaction, and will seek to resume trading in the Shares as soon as possible.

Among others, the Company is taking active steps to finalize the appointment of an independent forensic accountant or investigator to conduct the Independent Forensic Investigation, and an internal control consultant to conduct the Independent Internal Control Review.

The Board would like to express its appreciation for the longstanding support the Group has received from the relevant local governments, and Shanghai Biomedical Merger and Acquisition Equity Investment Partnership (Limited Partnership), Shanghai Pudong Leading Area Investment Center (Limited Partnership) and Shanghai Zhangjiang (Group) Co., Ltd. (each being an indirect shareholder of the Company). Subject to applicable disclosure requirements, the Board and management will maintain an active dialogue with these parties on the progress towards the resumption of trading in the Shares, the issues that the Group is facing and the steps it proposes to take to address them.

The Company will make further announcement(s) as and when appropriate and in accordance with the requirements of the Listing Rules to update its shareholders and potential investors on its progress in fulfilling the Resumption Guidance.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares (stock code: 853) and its debt securities (debt stock code: 40168) on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 September 2026. Pending fulfilment of the Resumption Guidance, trading in the Shares and the debt securities of the Company on the Stock Exchange will remain suspended until further notice.

This announcement may contain forward-looking statements based on the Company's current expectations and assumptions. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. The Company assumes no obligation to update any forward-looking statements. Shareholders of the Company, holders of debt securities of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company. If in doubt, shareholders of the Company, holders of debt securities of the Company and potential investors are advised to seek advice from their professional or financial advisers.

By order of the Board
MicroPort Scientific Corporation
Mr. Jonathan W. Chen
Executive Director

Shanghai, the PRC, 23 November 2026

As at the date of this announcement, the executive director of the Company is Mr. Jonathan W. Chen; the non-executive directors of the Company are Dr. Feng Gu, Ms. Jing Huang and Ms. Weiqin Sun; and the independent non-executive directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu, Mr. Chunyang Shao and Dr. Yingyao Chen.

* *For identification purposes only*